Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C
Shih-Jer Hsu(National Taiwan University Hospital), Wan‐Long Chuang(Kaohsiung Medical University), Albert Qin, Chao‐Wei Hsu, Rong‐Nan Chien(Chang Gung Memorial Hospital), Cheng‐Yuan Peng(China Medical University), Ming‐Lung Yu(National Sun Yat-sen University), Hsing‐Tao Kuo(Chi Mei Medical Center), Yi‐Wen Huang(University of Pisa), Wei-Wen Su(Changhua Christian Hospital), Hsien-Hong Lin(Taipei Tzu Chi Hospital), Kuan-Chiao Tseng(Efficient Pharma Management (Taiwan)), Sheng-Shun Yang(Taichung Veterans General Hospital), Gin‐Ho Lo(E-Da Hospital), Sien-Sing Yang(Taichung Veterans General Hospital), Chien‐Wei Su(National Yang Ming Chiao Tung University)
Cited by 22
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364